[Seraspenide (acetylSDKP): phase I-II trial study of inhibitor of hematopoiesis protects against toxicity of aracytine and ifosfamide monochemotherapies].
Seraspenide, a synthetic tetrapeptide, inhibits cell cycle entry of normal hematopoietic stem cells. In mice it protects hemopoiesis against the damage caused by cytarabine, cyclophosphamide and carboplatin. Seraspenide has been given to 53 cancer patients undergoing monochemotherapy with cytarabine and ifosfamide in a double-blind cross-over randomized study. A significant protection of peripheral blood cells has been observed. Seraspenide has been devoided of toxicity.
Carde
P
P
Institut Gustave-Roussy, Villejuif.
Chastang
C
C
Goncalves
E
E
Mathieu-Tubiana
N
N
Vuillemin
E
E
Delwail
V
V
Corbion
O
O
Vekhoff
A
A
Isnard
F
F
Ferrero
J M
JM
D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004311:Double-Blind Method; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D009842:Oligopeptides / Q000494:pharmacology* / Q000627:therapeutic use
D009842:Oligopeptides; D003561:Cytarabine; C058504:goralatide; D007069:Ifosfamide
Séraspénide (acétylSDKP): étude en phase I-II d'un inhibiteur de l'hématopoïèse la protégeant de la toxicité de monochimiothérapies aracytine et ifosfamide.